Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target
Authors:
- Matthias A. KarajannisMKMatthias A. Karajannis
- David ZagzagDZDavid Zagzag
- Smit ShahSSSmit Shah
- Iren Horkayne-SzakalyIHIren Horkayne-Szakaly
- Elisabeth J. RushingERElisabeth J. Rushing
- J. Douglas CameronJCJ. Douglas Cameron
- Deepali JainDJDeepali Jain
- Charles G. EberhartCECharles G. Eberhart
- Eric H. RaabeEREric H. Raabe
- Fausto J. RodriguezFRFausto J. Rodriguez
Open Access
- 1 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (12) , 1604-1614
Abstract
Previous studies support a role for mitogen-activated protein kinase pathway signaling, and more recently Akt/mammalian target of rapamycin (mTOR), in pediatric low-grade glioma (PLGG), including pilocytic astrocytoma (PA). Here we further evaluate the role of the mTORC1/mTORC2 pathway in order to better direct pharmacologic blockade in these common childhood tumors. We studied 177 PLGGs and PAs using immunohistochemistry and tested the effect of mTOR blockade on 2 PLGG cell lines (Res186 and Res259) in vitro. Moderate (2+) to strong (3+) immunostaining was observed for pS6 in 107/177 (59%) PAs and other PLGGs, while p4EBP1 was observed in 35/115 (30%), pElF4G in 66/112 (59%), mTOR (total) in 53/113 (47%), RAPTOR (mTORC1 component) in 64/102 (63%), RICTOR (mTORC2 component) in 48/101 (48%), and pAkt (S473) in 63/103 (61%). Complete phosphatase and tensin homolog protein loss was identified in only 7/101 (7%) of cases. In PA of the optic pathways, compared with other anatomic sites, there was increased immunoreactivity for pS6, pElF4G, mTOR (total), RICTOR, and pAkt (P < .05). We also observed increased pS6 (P = .01), p4EBP1 (P = .029), and RICTOR (P = .05) in neurofibromatosis type 1 compared with sporadic tumors. Treatment of the PLGG cell lines Res186 (PA derived) and Res259 (diffuse astrocytoma derived) with the rapalog MK8669 (ridaforolimus) led to decreased mTOR pathway activation and growth. These findings suggest that the mTOR pathway is active in PLGG but varies by clinicopathologic subtype. Additionally, our data suggest that mTORC2 is differentially active in optic pathway and neurofibromatosis type 1–associated gliomas. MTOR represents a potential therapeutic target in PLGG that merits further investigation.Keywords
This publication has 36 references indexed in Scilit:
- Pediatric Low-Grade GliomasJournal of Child Neurology, 2009
- Duplication of 7q34 in Pediatric Low‐Grade Astrocytomas Detected by High‐Density Single‐Nucleotide Polymorphism‐Based Genotype Arrays Results in a Novel BRAF Fusion GeneBrain Pathology, 2009
- The Pharmacology of mTOR InhibitionScience Signaling, 2009
- Molecular and Phenotypic Characterisation of Paediatric Glioma Cell Lines as Models for Preclinical Drug DevelopmentPLOS ONE, 2009
- Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytomaOncogene, 2009
- Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signatureBrain, 2009
- Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomasThe Journal of Pathology, 2009
- Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic AstrocytomasCancer Research, 2008
- BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasJournal of Clinical Investigation, 2008
- Loss ofNF1Alleles Distinguish Sporadic from NF1-Associated Pilocytic AstrocytomasJournal of Neuropathology & Experimental Neurology, 2001